Brazilian Experience Using High-dose Sequential Chemotherapy Followed By Autologous Hematopoietic Stem Cell Transplantation For Relapsed Or Refractory Hodgkin Lymphoma.

dc.creatorDuarte, Bruno K L
dc.creatorValente, Isabella
dc.creatorVigorito, Afonso C
dc.creatorAranha, Francisco J P
dc.creatorOliveira-Duarte, Gislaine
dc.creatorMiranda, Eliana C M
dc.creatorLorand-Metze, Irene
dc.creatorPagnano, Katia B
dc.creatorDelamain, Marcia
dc.creatorMarques Junior, José F
dc.creatorBrandalise, Silvia R
dc.creatorNucci, Márcio
dc.creatorDe Souza, Carmino A
dc.date2009-Dec
dc.date2015-11-27T13:15:42Z
dc.date2015-11-27T13:15:42Z
dc.date.accessioned2018-03-29T01:09:43Z
dc.date.available2018-03-29T01:09:43Z
dc.identifierClinical Lymphoma & Myeloma. v. 9, n. 6, p. 449-54, 2009-Dec.
dc.identifier1938-0712
dc.identifier10.3816/CLM.2009.n.088
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/19951885
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/198544
dc.identifier19951885
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1298777
dc.descriptionWe evaluate the effectiveness and toxicity of high-dose sequential chemotherapy (HDS) as salvage therapy in patients with advanced-stage Hodgkin lymphoma. We performed a retrospective analysis on 77 patients receiving HDS between 1998 and 2006. Patients enrolled were in disease progression or relapsed disease, or did not achieve a complete remission after first-line treatment. HDS consisted of the sequential administration of cyclophosphamide and granulocyte colony-stimulating factor with stem cell harvesting, followed by methotrexate plus vincristine and etoposide. The majority of patients had stage III/IV (64%) and B symptoms (71.4%). Disease status improvement after HDS was observed in 24 of 57 patients (42%) previously in disease progression or relapse. HDS-related deaths occurred in 8 of 77 patients (10.4%). Four patients (5.2%) developed acute myeloid leukemia/myelodysplastic syndrome. Overall, disease-free and progression-free survival was 27%, 57%, and 25%, respectively. Despite the treatment-related mortality, HDS is feasible, with satisfactory response rates, even in patients with poor prognosis.
dc.description9
dc.description449-54
dc.languageeng
dc.relationClinical Lymphoma & Myeloma
dc.relationClin Lymphoma Myeloma
dc.rightsaberto
dc.rights
dc.sourcePubMed
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectChild
dc.subjectDisease-free Survival
dc.subjectFemale
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectHodgkin Disease
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRecurrence
dc.subjectRetrospective Studies
dc.subjectTransplantation, Autologous
dc.titleBrazilian Experience Using High-dose Sequential Chemotherapy Followed By Autologous Hematopoietic Stem Cell Transplantation For Relapsed Or Refractory Hodgkin Lymphoma.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución